AVIEW LCS vs VX1
AI Verdict
Choose AVIEW LCS if…
Choose AVIEW LCS if your radiology department requires an AI-powered solution for comprehensive lung cancer screening and cardiopulmonary assessment. This tool is ideal for automating the detection and analysis of lung nodules, quantifying emphysema, and scoring coronary artery calcification from a single low-dose CT scan, thereby enhancing diagnostic accuracy and streamlining reporting workflows.
View AVIEW LCS →Choose VX1 if…
Choose VX1 if your electrophysiology lab seeks real-time AI guidance during atrial fibrillation and atrial tachycardia ablation procedures. This software is specifically designed to assist cardiac electrophysiologists in identifying dispersed electrograms, aiming to reduce inter-operator variability and standardize outcomes during complex cardiac ablations.
View VX1 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AVIEW LCS | VX1 |
|---|---|---|
| Pricing | Subscription or one-off payment | Contact for pricing |
| Deployment | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) | Software integrated with existing electrophysiology (EP) lab mapping and recording systems. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AVIEW LCSAVIEW LCS offers flexible deployment options (cloud, hybrid, local, virtualized) and integrates broadly with standard radiology workflows like PACS/RIS, making it easier to adopt into existing hospital IT infrastructure. Its automated report generation and ability to create patient-facing reports also enhance usability for a wider range of users and communication needs. VX1, while having a simple real-time interface, is highly specialized for EP labs and integrates with specific EP systems, limiting its broader applicability.
Clinical Value
AVIEW LCSAVIEW LCS provides a comprehensive, multi-disease assessment (lung cancer, COPD, coronary artery calcification) from a single low-dose CT scan, offering broad diagnostic and screening value across multiple prevalent conditions. Multiple studies validate its performance in reducing false negatives and workload for radiologists. While VX1 offers significant real-time guidance during complex AF ablation procedures, AVIEW LCS's broader impact on early detection and patient pathways for several major diseases gives it a slight edge in overall clinical utility.
Pricing & Value
AVIEW LCSBoth tools require contacting the vendor for pricing, lacking transparency. However, AVIEW LCS explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are crucial for data governance and add significant value in the healthcare sector. Furthermore, studies indicate AVIEW LCS can lead to substantial workload reduction and improved ROI, providing a more concrete value proposition.
Enterprise Readiness
AVIEW LCSAVIEW LCS demonstrates higher enterprise readiness through its explicit HIPAA compliance, BAA availability, and GDPR compliance, which are fundamental for healthcare IT adoption. Its diverse deployment options (cloud, hybrid, local) and integration with PACS/RIS, along with multi-site workflow management capabilities (AVIEW HUB), cater to complex hospital IT environments. VX1 lacks explicit statements on HIPAA/BAA in the provided information, and its integration is more specialized for EP labs.
Innovation
VX1VX1 stands out for its real-time, AI-guided decision support during live, complex interventional procedures like atrial fibrillation ablation, directly influencing physician actions during a critical moment. This application of AI to reduce inter-operator variability and standardize outcomes in a highly skilled, dynamic clinical setting represents a significant innovative leap. While AVIEW LCS offers innovative multi-disease assessment and automation of diagnostic workflows, VX1's in-procedure, interactive guidance is arguably a higher degree of innovation in terms of immediate clinical impact.
Support & Docs
TieBoth tools provide evidence of user manuals and documentation. AVIEW LCS mentions 'Support documentation' and references FDA documents containing user information. VX1 explicitly references its 'VX1 SYSTEM USER MANUAL' multiple times across its website and related publications. Without further specific details on the quality, accessibility, or scope of support services, it is difficult to distinguish between the two.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AVIEW LCS | VX1 |
|---|---|---|
| Name | AVIEW LCS | VX1 |
| Company | Coreline Soft Co. | Volta Medical |
| Primary Use Case | AI-powered solution for the detection and analysis of lung nodules, lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan. | FDA-cleared AI software that assists cardiac electrophysiologists in real-time identification of dispersed electrograms during atrial fibrillation and atrial tachycardia ablation procedures. |
| Categories | Cardiology AI, Oncology AI, Radiology & Imaging AI | Cardiology AI, Surgical AI |
| Specialties | Cardiology, Oncology, Pulmonology, Radiology | Cardiology |
| Key AI Functionality | Automated lung nodule detection and analysis, Lung-RADS classification and reporting, Emphysema quantification, Coronary Artery Calcification (CAC) scoring. | AI-guided real-time identification of dispersed electrograms (EGMs), analyzes 3D anatomical and electrical maps of human atria. |
Videos
Demos, reviews, and walkthroughs featuring AVIEW LCS and VX1.